Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recent Advances in Human Natural Killer Cells.

International archives of allergy and immunology·2021
Same author

Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia.

Leukemia·2019
Same author

IL15 induces a potent antitumor activity in NK cells isolated from malignant pleural effusions and overcomes the inhibitory effect of pleural fluid.

Oncoimmunology·2017
Same author

Zoledronic acid boosts γδ T-cell activity in children receiving αβ<sup>+</sup> T and CD19<sup>+</sup> cell-depleted grafts from an HLA-haplo-identical donor.

Oncoimmunology·2017
Same author

Role of Nrf2, HO-1 and GSH in Neuroblastoma Cell Resistance to Bortezomib.

PloS one·2016
Same author

Group 3 innate lymphoid cells regulate neutrophil migration and function in human decidua.

Mucosal immunology·2016

Related Experiment Video

Updated: Dec 23, 2025

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.8K

Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28.

F R Mariotti1, L Quatrini1, E Munari2

  • 1Department of Immunology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.

British Journal of Pharmacology
|April 27, 2020
PubMed
Summary

Natural killer (NK) cells are crucial for anti-tumour immunity. Targeting inhibitory checkpoints like programmed cell death protein 1 (PD-1) on NK cells may enhance cancer immunotherapy efficacy, especially in non-responders.

More Related Videos

Measurement of Natural Killer Cell-Mediated Cytotoxicity and Migration in the Context of Hepatic Tumor Cells
06:55

Measurement of Natural Killer Cell-Mediated Cytotoxicity and Migration in the Context of Hepatic Tumor Cells

Published on: February 22, 2020

19.3K
Assessment of Human Natural Killer Cell Events Driven by Fc&#947;RIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.8K

Related Experiment Videos

Last Updated: Dec 23, 2025

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.8K
Measurement of Natural Killer Cell-Mediated Cytotoxicity and Migration in the Context of Hepatic Tumor Cells
06:55

Measurement of Natural Killer Cell-Mediated Cytotoxicity and Migration in the Context of Hepatic Tumor Cells

Published on: February 22, 2020

19.3K
Assessment of Human Natural Killer Cell Events Driven by Fc&#947;RIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.8K

Area of Science:

  • Immunology
  • Cancer Biology
  • Immunotherapy

Background:

  • Immune checkpoint inhibitors have transformed cancer treatment but face limitations in non-responder patients.
  • Natural killer (NK) cells are vital innate immune cells with potent anti-tumour capabilities.
  • NK cell receptors and their inhibitory checkpoints are emerging targets for novel cancer therapies.

Purpose of the Study:

  • To review the expression of NK cell receptors in cancer.
  • To focus on the role of programmed cell death protein 1 (PD-1) as an inhibitory checkpoint on NK cells.
  • To explore strategies for enhancing NK cell anti-tumour responses through PD-1 pathway modulation.

Main Methods:

  • Literature review of recent evidence on NK cell receptor expression in cancer.
  • Analysis of the role and expression of PD-1 on NK cells within the tumour microenvironment.
  • Evaluation of current PD-1 blockade strategies and their impact on NK cell function.

Main Results:

  • NK cells express various receptors, including inhibitory checkpoints like PD-1, which can be dysregulated in cancer.
  • PD-1 blockade can potentially enhance NK cell anti-tumour activity, but its efficacy is context-dependent.
  • Limitations exist in current PD-1 blockade approaches, necessitating further research into combination strategies.

Conclusions:

  • Modulating NK cell inhibitory checkpoints, particularly PD-1, offers a promising avenue for next-generation cancer immunotherapy.
  • Combination strategies are essential to overcome PD-1 pathway limitations and maximize NK cell-mediated anti-tumour responses.
  • Further research is warranted to fully harness NK cell potential in cancer treatment.